Research Topic: pain management

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Read More »

Social pain: A systematic review on interventions

mycolabadmin

This study reviews different treatments for social pain—the emotional hurt from rejection and social exclusion. Researchers found that regular pain reliever acetaminophen, mindfulness meditation, and the psychedelic compound psilocybin can reduce social pain, while placebo pills also help when people believe they work. Interestingly, combining acetaminophen with forgiveness works better than either alone, suggesting that both physical and emotional pain may use similar brain pathways.

Read More »

A systematic review to assess the use of psilocybin in the treatment of headaches

mycolabadmin

Researchers reviewed eight studies examining whether psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, could treat various types of headaches and migraines. Most studies found that psilocybin provided clinically significant relief, with participants experiencing improvements in how often they got headaches, how intense they were, and how long they lasted. However, some users experienced side effects like hallucinations or temporary increases in anxiety, and the compound remains illegal in most countries, limiting current research.

Read More »

Ethical Considerations Regarding Psychedelics for Clinical Pain Research

mycolabadmin

This paper examines the ethical considerations necessary when conducting research on psychedelics like psilocybin for treating chronic pain. With chronic pain affecting millions of Americans and traditional treatments like opioids causing significant problems, researchers are exploring psychedelics as alternatives. The authors provide guidance on obtaining proper informed consent, protecting vulnerable patients, managing regulatory requirements, and ensuring research benefits participants while following four key ethical principles: autonomy, beneficence, justice, and avoiding harm.

Read More »

Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain

mycolabadmin

Researchers found that psilocybin, the active ingredient in magic mushrooms, significantly reduced chronic pain in mice through activation of specific serotonin receptors. The effects lasted for up to two weeks after a single dose, suggesting lasting changes in how the nervous system processes pain. This study suggests psilocybin could be a promising new treatment for chronic pain conditions like neuropathy and inflammation.

Read More »

Rac1/PAK1 signaling contributes to bone cancer pain by regulation dendritic spine remodeling in rats

mycolabadmin

Researchers studied how bone cancer pain develops in rats and found that a specific cellular signaling pathway called Rac1/PAK1 plays a key role. When tumors grow in bone, this pathway becomes overactive and causes changes in nerve cell structures called dendritic spines, which leads to increased pain sensitivity. By blocking this pathway with a drug called NSC23766, scientists were able to reduce pain and reverse the harmful changes to nerve cells, suggesting a new potential treatment approach for cancer patients suffering from bone pain.

Read More »
Scroll to Top